started · updated
Thermo Fisher Scientific reports third quarter growth and raises outlook
Thermo Fisher Scientific has reported third-quarter fiscal 2026 results that exceeded analyst expectations for both revenue and adjusted earnings per share (EPS). Total revenue rose 9% year-over-year to $12.14 billion, driven by a 15% increase in the laboratory products and biopharmaceutical services segment, which reached $6.86 billion.
Adjusted operating income grew by 15% to $2.97 billion, with adjusted operating margins increasing to 24.5%. While the Life Sciences division saw a 5.1% increase to $2.72 billion, this figure fell slightly short of analyst estimates. Additionally, the specialized diagnostics segment experienced a 6.5% decline, totaling $1.10 billion.
Following these results, the company raised its full-year 2026 guidance. The updated revenue projection is now between $47.7 billion and $48.2 billion, up from the previous range of $47.3 billion to $48.1 billion. The company also increased its adjusted EPS forecast to a range of $25.13 to $25.43.